Physician profile
Michael Gordon
NPI 1689136137
$5,494.89
in general payments reported to CMS, 2019-2025
26 companies · $2,224 in 2025
The $2,224 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $1,197 · 2023: $703 · 2024: $1,028 · 2025: $2,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,886 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,885.73 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.07 | 2022-2025 | |
| Incyte Corporation | $758.51 | 2022-2025 | Opzelura |
| Genzyme Corporation | $516.50 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $371.41 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $297.53 | 2021-2025 | Dupixent, Libtayo |
| Journey Medical Corporation | $287.45 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $253.28 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $245.53 | 2021-2025 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $224.54 | 2024-2025 | Tremfya |
| Ucb, INC. | $196.42 | 2023-2024 | Bimzelx, Cimzia |
| Lilly USA, LLC | $164.25 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $163.07 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.45 | 2022-2024 | Spevigo |
| Leo Pharma INC. | $150.26 | 2025 | Adbry, Anzupgo |
| Amgen INC. | $146.51 | 2022-2025 | Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $118.04 | 2022 | |
| Arcutis Biotherapeutics, INC. | $102.72 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $82.69 | 2025 | |
| Nobelpharma America, LLC | $46.77 | 2023-2025 | |
| Organon LLC | $46.23 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.28 | 2023 | Siliq |
| Cipher Pharmaceuticals US LLC | $29.17 | 2025 | Natroba, Spinosad |
| Strata Skin Sciences, INC. | $22.52 | 2025 | Xtrac |
| Dermavant Sciences, INC. | $19.63 | 2024 | Vtama |
| Biofrontera INC. | $14.85 | 2022 | |
| Genentech USA, INC. | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.